VANI
Vivani Medical, Inc. NASDAQ Listed Nov 19, 2014$1.14
Mkt Cap $67.3M
52w Low $0.92
21.8% of range
52w High $1.92
50d MA $1.23
200d MA $1.31
P/E (TTM)
—
EV/EBITDA
—
P/B
4.5x
Debt/Equity
1.2x
ROE
-169.2%
P/FCF
-3.0x
RSI (14)
34.80
ATR (14)
$0.06
Beta
3.37
50d MA
$1.23
200d MA
$1.31
Avg Volume
190.1K
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
5858 Horton Street · Alameda, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.09 | -0.09 | +0.0% | 1.08 | -1.9% | -5.6% | -8.0% | +6.6% | +0.0% | +8.0% | — |
| Nov 13, 2025 | AMC | -0.12 | -0.11 | +8.3% | 1.36 | +0.0% | +4.4% | +3.5% | -4.1% | -2.8% | -1.5% | — |
| Aug 13, 2025 | AMC | -0.10 | -0.12 | -20.0% | 1.26 | -1.6% | +0.8% | -1.6% | -0.8% | -2.4% | +0.8% | — |
| May 13, 2025 | AMC | -0.10 | -0.11 | -10.0% | 1.05 | -1.0% | -3.8% | +2.0% | +0.0% | +3.9% | +7.5% | — |
| Mar 31, 2025 | AMC | -0.10 | -0.11 | -10.0% | 1.05 | +0.0% | -2.9% | -1.0% | -2.0% | -3.0% | +6.2% | — |
| Nov 13, 2024 | AMC | -0.11 | -0.11 | +0.0% | 1.39 | +1.4% | +3.6% | -9.0% | +0.8% | -2.3% | +0.0% | — |
| Aug 13, 2024 | AMC | -0.12 | -0.10 | +16.7% | 1.16 | -0.9% | +8.6% | +0.8% | +0.8% | +6.2% | +1.5% | — |
| May 13, 2024 | AMC | -0.12 | -0.12 | +0.0% | 1.85 | -4.3% | -1.1% | +4.4% | +3.1% | +1.5% | -8.0% | — |
| Mar 26, 2024 | AMC | -0.14 | -0.12 | +14.3% | 1.88 | +1.1% | -1.6% | +0.0% | +7.0% | -5.1% | +8.5% | — |
| Nov 14, 2023 | AMC | -0.13 | -0.13 | +0.0% | 0.96 | -3.3% | -0.6% | +0.0% | +3.0% | -2.8% | -0.1% | — |
| Aug 14, 2023 | AMC | -0.11 | -0.13 | -18.2% | 1.22 | -1.6% | -10.7% | +3.7% | -2.7% | -7.3% | -5.8% | — |
| May 15, 2023 | AMC | -0.11 | -0.12 | -9.1% | 1.30 | +0.0% | -10.0% | +7.7% | +2.4% | +8.5% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.94 | $0.95 | +1.1% | +6.6% | +0.0% | +8.0% | +2.8% | -4.5% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.14 | -0.9% | +0.9% | +0.0% | +18.1% | -5.8% | -0.8% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.04 | +1.0% | +3.9% | +7.5% | -1.7% | +0.9% | -0.9% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.03 | +0.0% | +1.9% | +1.0% | -3.8% | +0.0% | +1.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.99 | $0.99 | +0.0% | -3.0% | +6.2% | +0.0% | +2.9% | -3.8% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.10 | $1.10 | +0.0% | +1.8% | +2.7% | -3.5% | -5.4% | -2.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.10 | +5.8% | +1.9% | +2.8% | +0.9% | -0.9% | +0.9% |
| Dec 5 | ThinkEquity | Maintains | Buy → Buy | — | $1.38 | $1.45 | +5.1% | +32.6% | -4.9% | -1.1% | -1.7% | -4.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Williams GreggDir | — | Buy | 1,587,301 | $1.26 | $2.0M | 36,119,086 | -1.71% | +0.84% |
| May 15, 2026 | Williams GreggDir | — | Buy | 1,587,301 | $1.26 | $2.0M | 34,531,785 | +3.48% | +3.23% |
8-K · 7.01
! Medium
Vivani Medical, Inc. -- 8-K 7.01: Regulation FD Disclosure
Vivani Medical's CEO will present at the Jefferies Global Healthcare Conference on June 4, 2026, providing investors opportunity to hear directly about company strategy and updates.
Jun 4
8-K
Unknown — 8-K Filing
Vaniam's semaglutide implant shows durable weight loss efficacy with runway through mid-2027, de-risking development but requiring Phase 1 success in NPM-139 to validate the platform's commercial potential.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,530,933 | $2M | New | Mar 2026 |
| 2 | Tanager Wealth Management Llp | 641,085 | $641K | Reduced | Mar 2026 |
| 3 | Tudor Investment Corp | 426,302 | $426K | New | Mar 2026 |
| 4 | Commonwealth Equity Services, Llc | 330,530 | $407K | — | Dec 2025 |
| 5 | Ubs Group Ag | 337,749 | $338K | Added | Mar 2026 |
| 6 | Northern Trust Corp | 96,461 | $96K | Added | Mar 2026 |
| 7 | Marshall Wace, Llp | 92,269 | $92K | Reduced | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 86,286 | $86K | Reduced | Mar 2026 |
| 9 | Simplex Trading, Llc | 68,199 | $68K | New | Mar 2026 |
| 10 | Armstrong Advisory Group, Inc | 65,000 | $65K | New | Mar 2026 |
| 11 | Jane Street Group, Llc | 48,574 | $60K | New | Dec 2025 |
| 12 | Renaissance Technologies Llc | 37,295 | $37K | Reduced | Mar 2026 |
| 13 | Lazari Capital Management, Inc. | 10,000 | $12K | — | Dec 2025 |
| 14 | Kestra Private Wealth Services, Llc | 12,216 | $12K | New | Mar 2026 |
| 15 | Catalyst Funds Management Pty Ltd | 12,200 | $12K | New | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 3,491 | $3K | New | Mar 2026 |
| 17 | Fmr Llc | 2,324 | $2K | New | Mar 2026 |
| 18 | Steward Partners Investment Advisory, Llc | 2,000 | $2K | — | Mar 2026 |
| 19 | Morgan Stanley | 682 | $838 | Reduced | Dec 2025 |
| 20 | Innovative Asset Advisors Group, Llc | 5 | $5 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 248,550 | $306K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 130,234 | $130K | Mar 2026 |
| 3 | Fidelity Series Total Market Index Fund | 61,929 | $76K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 58,567 | $72K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 37,626 | $46K | Feb 2026 |
| 6 | Schwab Total Stock Market Index Fund | 30,016 | $42K | Jan 2026 |
Valuation
Market Cap
$67.3M
Enterprise Value
$76.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
4.52x
P/S
—
P/FCF
-2.99x
EV/EBITDA
—
Shares Out
62.4M
Financials (TTM)
Revenue
$0
Net Income
-$27.1M
EBITDA
-$26.6M
Free Cash Flow
-$25.5M
Op Cash Flow
-$24.3M
EPS Basic
$-0.43
EPS Diluted
$-0.40
EPS Forward
$-0.33
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$39.4M
Total Liab.
$23.7M
Total Equity
$15.7M
Cash
$16.2M
LT Debt
$17.1M
Book Value/Sh
$0.25
Debt/Equity
1.20x
Current Ratio
2.71
Quick Ratio
2.71
Returns & Growth
ROE
-169.2%
ROA
-67.5%
ROIC
-79.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
—
Price Returns
2W
+10.0%
1M
-1.5%
3M
+7.3%
6M
-2.9%
12M
+4.8%
Technicals
52W High
$1.92
52W Low
$0.92
50d MA
$1.23
200d MA
$1.31
RSI (14)
34.80
ATR (14)
$0.06
Beta
3.37
Avg Volume
190K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 7:21am
· Source: financialmodelingprep.com